Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas

Abstract excerpt

BACKGROUND: Glioblastoma is the most lethal primary malignant brain tumor. Although considerable progress has been made in the treatment of this aggressive tumor, the clinical outcome for patients remains poor. Histone deacetylases (HDACs) are recognized as promising targets for cancer treatment. In the past several years, HDAC inhibitors (HDACis) have been used as radiosensitizers in glioblastoma treatment....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epigenetics and DNA Methylation
• Share to Glioma Diagnosis and Treatment
• Share to Histone Deacetylase Inhibitors Research